ARC
HZNP

Advisor Resource Council’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Advisor Resource Council’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,724
Closed -$1.01M – 538
2022
Q2 		$1.01M Buy
12,724
+7,616
+149% +$721K 0.09% 194
2022
Q1 		$537K Buy
+5,108
New +$498K 0.16% 131

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Advisor Resource Council's HZNP Position: Q3 2022 in Review

Advisor Resource Council sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 12,724 shares — an estimated $1.01M sold.

Advisor Resource Council first reported a position in HZNP in Q1 2022 and held it in 2 quarters. The position peaked at $1.01M in Q2 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • Advisor Resource Council reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Advisor Resource Council sold 12,724 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $1.01M.
  • Advisor Resource Council first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 2 quarters.
  • Advisor Resource Council's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.01M in Q2 2022.
  • 530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Advisor Resource Council's 13F filing for Q3 2022, filed 26 Oct 2022.